This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.
Patients with multiple myeloma
Number of approved sites
M1000 Biobank participants
The MRDR supports Rare Disease Day 2024.Read more
Sueh-li Lim's paper on Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments has been published.Read more